Deacylated alfuzosin (CAS No: 76362-29-3) is a key pharmaceutical intermediate used in the synthesis of APIs Alfuzosin. This compound serves as an essential raw material in API development and synthesis. Explore detailed chemical properties, molecular data, structure information, and verified global suppliers, manufacturers, and distributors of this API intermediate on apicule.
Alternate Names: 2,4-Quinazolinediamine, N2-(3-aminopropyl)-6,7-dimethoxy-N2-methyl-, N-(4-Amino-6,7-dimethoxyquinazolin-2-yl)-N-methylpropane-1,3-diamine
CAS No: 76362-29-3
PubChem CID: 13544733
Mol Formula: C14H21N5O2
Mol Weight: 291.35 g/mol
Used in API: Alfuzosin
IUPAC Name: 2-N-(3-aminopropyl)-6,7-dimethoxy-2-N-methylquinazoline-2,4-diamine
API Intermediate Description: Deacylated alfuzosin, also known as alfuzosin aminopropyl impurity (Alfuzosin EP Impurity D), has no therapeutic use as a drug itself; it is an inactive metabolite and an impurity standard used in pharmaceutical development and quality control. The active drug, alfuzosin, is used to treat symptoms of an enlarged prostate (benign prostatic hyperplasia, or BPH).
